Pentraxin‐3 level at admission is a strong predictor of short‐term mortality in a community‐based hospital setting

Bastrup-Birk, S.; Munthe-Fog, Lea; Skjoedt, Mikkel Ole; Ma, Y. J.; Nielsen, Henrik; Køber, Lars; Nielsen, Olav Wendelboe; Iversen, Kasper; Garred, Peter

doi:10.1111/joim.12294

Cited by 22 publications

(27 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29,30 It has been shown to be beneficial as a marker for many diseases like cardiovascular disease, malignancies, and some specific infections. [31][32][33][34][35] Adult studies have shown serum levels increase with sepsis and septic shock. 36,37 A study of a newborn patient group including premature babies compared the pentraxin 3 values of mothers and babies with early membrane rupture with neonatal results and found it was associated with intraventricular hemorrhage and mortality.…”

Section: Discussionmentioning

confidence: 99%

Serum Pentraxin 3 Concentration in Neonatal Sepsis

Battal

Bulut

Yıldırım

et al. 2019

J Pediatr Infect Dis

View full text Add to dashboard Cite

Objective Neonatal sepsis is one of the most important causes of neonatal morbidity and mortality. Symptoms and signs of neonatal sepsis can be silent; therefore, laboratory investigation is necessary in cases of doubt or if there are risk factors. Early diagnosis is important for early intervention and treatment. The most valuable method for diagnosis is blood culture; however, false positivity due to contamination or false negativity despite ongoing fatal bacterial infections can be seen. Pentraxin 3 is a prototype of the long pentraxin family. It has some differences from C-reactive protein (CRP) in terms of gene organization and localization and production site. It is effective in the early phase of inflammation and it is detected as an early marker of sepsis in adults. The aim of this study was to investigate whether pentraxin 3 can be used as a marker in neonatal sepsis. Materials and Methods Thirty newborns with suspected sepsis with antenatal history or the presence of clinical signs of sepsis, such as hypo/hyperthermia, feed intolerance, lethargy, hypotonia, irregular cardiac rhythms, bradycardia, cyanosis, apnea, respiratory distress, or metabolic acidosis, were enrolled in the study as a case group, and 28 healthy newborns were included as a control group. Serum pentraxin 3, procalcitonin, CRP, and hemogram in the study group and serum procalcitonin and pentraxin in the control group were examined. Results Serum pentraxin 3 (pg/mL) and serum procalcitonin (ng/mL) levels were 2,273.82 ± 1,260.75 and 0.86 ± 0.52 in the case group and 957.41 ± 268.00 and 0.19 ± 0.18 in the control group (p < 0.001 for both), respectively. Conclusion The present study showed that serum pentraxin 3 levels may be a useful marker in the diagnosis of neonatal sepsis.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Pentraxin 3 Concentration in Neonatal Sepsis

Battal

Bulut

Yıldırım

et al. 2019

J Pediatr Infect Dis

View full text Add to dashboard Cite

show abstract

“…However, it has also been shown that the standard blood panel have only limited predictive power in risk assessment when added to physiological parameters [ 26 ], future studies can reveal whether prognostic information can be significantly improved using a whole panel of new and old inflammatory biomarkers. Several biomarkers have shown prognostic strength, for example C-reactive protein, suPAR, YKL-40, Pentraxin-3, Copeptin and Troponin T [ 11 – 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…Several old and new biomarkers are useful to estimate short term prognosis [ 11 – 16 ] and a recent theoretical study has suggested that the use of biomarkers would substantially strengthen the existing triage algorithms [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

The formation and design of the TRIAGE study - baseline data on 6005 consecutive patients admitted to hospital from the emergency department

Plesner

Iversen

Langkjær

et al. 2015

Scand J Trauma Resusc Emerg Med

View full text Add to dashboard Cite

BackgroundPatient crowding in emergency departments (ED) is a common challenge and associated with worsened outcome for the patients. Previous studies on biomarkers in the ED setting has focused on identification of high risk patients, and and the ability to use biomarkers to identify low-risk patients has only been sparsely examined. The broader aims of the TRIAGE study are to develop methods to identify low-risk patients appropriate for early ED discharge by combining information from a wide range of new inflammatory biomarkers and vital signs, the present baseline article aims to describe the formation of the TRIAGE database and characteristize the included patients.MethodsWe included consecutive patients ≥ 17 years admitted to hospital after triage staging in the ED. Blood samples for a biobank were collected and plasma stored in a freezer (−80 °C). Triage was done by a trained nurse using the Danish Emergency Proces Triage (DEPT) which categorizes patients as green (not urgent), yellow (urgent), orange (emergent) or red (rescusitation). Presenting complaints, admission diagnoses, comorbidities, length of stay, and ‘events’ during admission (any of 20 predefined definitive treatments that necessitates in-hospital care), vital signs and routine laboratory tests taken in the ED were aslo included in the database.ResultsBetween September 5th 2013 and December 6th 2013, 6005 patients were included in the database and the biobank (94.1 % of all admissions). Of these, 1978 (32.9 %) were categorized as green, 2386 (39.7 %) yellow, 1616 (26.9 %) orange and 25 (0.4 %) red. Median age was 62 years (IQR 46–76), 49.8 % were male and median length of stay was 1 day (IQR 0–4). No events were found in 2658 (44.2 %) and 158 (2.6 %) were admitted to intensive or intermediate-intensive care unit and 219 (3.6 %) died within 30 days. A higher triage acuity level was associated with numerous events, including acute surgery, endovascular intervention, i.v. treatment, cardiac arrest, stroke, admission to intensive care, hospital transfer, and mortality within 30 days (p < 0.001).ConclusionThe TRIAGE database has been completed and includes data and blood samples from 6005 unselected consecutive hospitalized patients. More than 40 % experienced no events and were therefore potentially unnecessary hospital admissions.Electronic supplementary materialThe online version of this article (doi:10.1186/s13049-015-0184-1) contains supplementary material, which is available to authorized users.

show abstract

“…Primary pro‐inflammatory signals (bacterial components, pathogen‐associated molecular patterns, damage‐associated molecular patterns, IL‐1, TNF‐alpha) induce the synthesis and release of PTX3 in various cell types such as endothelial cells, polymorphonuclear leucocytes (PMN) and monocytes/macrophages . On account of its specific involvement in the immune system and inflammatory processes, and as it can be measured in blood, PTX3 has been characterized as a biomarker of disease severity and outcomes in different cardiovascular diseases, malignancies and specific infections . Since the first report , several studies have focused on the roles of elevated circulating PTX3 in sepsis and related complications such as shock.…”

Section: Introductionmentioning

confidence: 99%